These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12473583)

  • 21. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.
    Sheikh MS; Huang Y; Fernandez-Salas EA; El-Deiry WS; Friess H; Amundson S; Yin J; Meltzer SJ; Holbrook NJ; Fornace AJ
    Oncogene; 1999 Jul; 18(28):4153-9. PubMed ID: 10435597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin inhibits apoptosis induced by TRAIL, and the ratio between survivin and TRAIL receptors is predictive of recurrent disease in neuroblastoma.
    Azuhata T; Scott D; Griffith TS; Miller M; Sandler AD
    J Pediatr Surg; 2006 Aug; 41(8):1431-40. PubMed ID: 16863850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and function of death receptors and their natural ligands in the intestine.
    Sträter J; Möller P
    Ann N Y Acad Sci; 2000; 915():162-70. PubMed ID: 11193573
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.
    Leverkus M; Neumann M; Mengling T; Rauch CT; Bröcker EB; Krammer PH; Walczak H
    Cancer Res; 2000 Feb; 60(3):553-9. PubMed ID: 10676636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TRAIL induces death of human oligodendrocytes isolated from adult brain.
    Matysiak M; Jurewicz A; Jaskolski D; Selmaj K
    Brain; 2002 Nov; 125(Pt 11):2469-80. PubMed ID: 12390973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
    Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
    Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells.
    Wendling U; Walczak H; Dörr J; Jaboci C; Weller M; Krammer PH; Zipp F
    Cell Death Differ; 2000 Jul; 7(7):637-44. PubMed ID: 10889508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of tumor necrosis factor-alpha-related apoptosis-inducing ligand and its receptors in rat testis during development.
    Grataroli R; Vindrieux D; Gougeon A; Benahmed M
    Biol Reprod; 2002 Jun; 66(6):1707-15. PubMed ID: 12021051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections.
    Sträter J; Walczak H; Pukrop T; Von Müller L; Hasel C; Kornmann M; Mertens T; Möller P
    Gastroenterology; 2002 Mar; 122(3):659-66. PubMed ID: 11874999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S; Hammann A; Wotawa A; Corcos L; Solary E; Dimanche-Boitrel MT
    Cancer Res; 2001 Feb; 61(4):1645-51. PubMed ID: 11245478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.
    Sanlioglu AD; Dirice E; Aydin C; Erin N; Koksoy S; Sanlioglu S
    BMC Cancer; 2005 May; 5():54. PubMed ID: 15916713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Actinomycin D renders cultured synovial fibroblasts susceptible to tumour necrosis factor related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
    Park YW; Ji JD; Lee JS; Ryang DW; Yoo DH
    Scand J Rheumatol; 2003; 32(6):356-63. PubMed ID: 15080267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma.
    Arts HJ; de Jong S; Hollema H; ten Hoor K; van der Zee AG; de Vries EG
    Gynecol Oncol; 2004 Mar; 92(3):794-800. PubMed ID: 14984943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional expression of TRAIL receptors TRAIL-R1 and TRAIL-R2 in esophageal adenocarcinoma.
    Younes M; Georgakis GV; Rahmani M; Beer D; Younes A
    Eur J Cancer; 2006 Mar; 42(4):542-7. PubMed ID: 16426839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.
    McCarthy MM; Sznol M; DiVito KA; Camp RL; Rimm DL; Kluger HM
    Clin Cancer Res; 2005 Jul; 11(14):5188-94. PubMed ID: 16033835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptotic phenotype alters the capacity of tumor necrosis factor-related apoptosis-inducing ligand to induce human vascular endothelial activation.
    Chen PL; Easton A
    J Vasc Res; 2008; 45(2):111-22. PubMed ID: 17940338
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer.
    Liao Q; Friess H; Kleeff J; Büchler MW
    Anticancer Res; 2001; 21(5):3153-9. PubMed ID: 11848467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer.
    Labovsky V; Martinez LM; Davies KM; de Luján Calcagno M; García-Rivello H; Wernicke A; Feldman L; Matas A; Giorello MB; Borzone FR; Choi H; Howard SC; Chasseing NA
    BMC Cancer; 2017 Apr; 17(1):280. PubMed ID: 28420351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis.
    Hague A; Hicks DJ; Hasan F; Smartt H; Cohen GM; Paraskeva C; MacFarlane M
    Br J Cancer; 2005 Feb; 92(4):736-42. PubMed ID: 15685228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.